AskBorsa
ARSign up free
EGX·Health Care & Pharmaceuticals

Nile Pharmaceuticals

NIPH
Fiscal year starts in July · currency EGP · latest: Annual 2026
Next results: Q1 2027 — expected around 10 December 2026estimated from earlier disclosure datesResults calendar ←
274.00EGP+4.17% today1w +13.2%1m −17.5%delayed · 3 November
Net profit · 2024
90.23million
▼ 24.3% vs 2023
Total assets · 2024
1.47billion
▲ 41.9% vs 2023
Shareholders' equity · 2024
469million
▼ 2.0% vs 2023
Operating cash flow · 2024
264million
▲ 203.0% vs 2023

Key facts

Source: annual statements 2024
  • Nile Pharmaceuticals's net profit in 2024 was 90.23 million EGP, down 24.3% from 119 million EGP in 2023.
  • Total assets at the end of 2024 were 1.47 billion EGP, and shareholders' equity 469 million EGP.
  • Operating cash flow in 2024 was positive at 264 million EGP.

Nile Pharmaceuticals's Q1 2027 results are expected around 10 December — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Ask about Nile Pharmaceuticals
How much did Nile Pharmaceuticals's net profit grow last year?What were total assets and shareholders' equity in the latest annual balance sheet?Was operating cash flow positive in the last three years?Type your question…Ask
3 free questions a day after signing up. With Google, no password.
Annual net profit last 4 years
Net profit
64.42million
89.67million
119million
90.23million
2021202220232024

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP2021202220232024
Income statement
Net profit64.42 million89.67 million119 million90.23 million
Gross profit502 million535 million595 million298 million
Total assets720 million769 million1.04 billion1.47 billion
Total liabilities349 million339 million560 million1 billion
Shareholders' equity371 million431 million478 million469 million
Total liabilities and equity720 million769 million1.04 billion1.47 billion
Operating cash flow79.47 million4.91 million-256 million264 million
Investing cash flow-4.29 million-48 million-27.52 million-420 million
Financing cash flow-45.2 million-12.62 million273 million303 million
Net change in cash29.99 million-55.71 million-11.38 million148 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Q3 2026Q2 2026Q4 2025Q3 2025Q2 2025Q1 2025Fiscal year 2024Q4 2024Q3 2024Q2 2024Q1 2024Fiscal year 2023Q4 2023Q3 2023Q2 2023Q1 2023Fiscal year 2022Q4 2022Q3 2022Q2 2022Q1 2022Fiscal year 2021

Financial reports (17)

2026Annual
PDF
2026Q1
PDF
2026Q2
PDF
2026Q3
PDF
2025Q2
PDF
2025Q1
PDF
2025Annual
PDF
2024Q3
PDF
2024Q2
PDF
2024Annual
PDF
2024Q1
PDF
2023Q1
PDF
2022Q3
PDF
2022Q2
PDF
2022Q1
PDF
2022Annual
PDF
2021Annual
PDF

Other companies in Health Care & Pharmaceuticals

Ranked by latest annual net profit
All companies in the sector ←
EIPICOPHAR·1.1billion+33%Ibnsina PharmaISPH·952million+55%Cleopatra Hospitals GroupCLHO·824million+14%Alexandria PharmaceuticalsAXPH·660million+1132%Memphis PharmaceuticalsMPCI·480million−5%Cairo PharmaceuticalsCPCI·444million+80%